NCT06715943View on ClinicalTrials.gov

Efficacy and Safety of HRS-5965 in Patients With PNH Who Are Still Anemia After Anti-C5 Antibody Treatment

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 7, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Interventions

DRUG

HRS-5965 capsule

HRS-5965 capsule treatment

Trial Locations (2)

30000

Hematology Hospital of Chinese Academy of Medical Sciences, Tianjin

Tianjin Medical University General Hospital, Tianjin

All Listed Sponsors

lead

Chengdu Suncadia Medicine Co., Ltd.

INDUSTRY

NCT06715943 - Efficacy and Safety of HRS-5965 in Patients With PNH Who Are Still Anemia After Anti-C5 Antibody Treatment | Biotech Hunter | Biotech Hunter